We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · February 09, 2021

Long-Term Efficacy and Safety of Erenumab in Migraine Prevention

European Journal of Neurology

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Neurology
Long-Term Efficacy and Safety of Erenumab in Migraine Prevention: Results From a 5-Year, Open-Label Treatment Phase of a Randomized Clinical Trial
Eur. J. Neurol. 2021 Jan 05;[EPub Ahead of Print], M Ashina, PJ Goadsby, U Reuter, S Silberstein, DW Dodick, F Xue, F Zhang, G Paiva da Silva Lima, S Cheng, DD Mikol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading